Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin

Table 1 Analysis of All Drug-Related and Post-Therapy Adverse Events

Adverse Event	Placebo + Metformin (N = 17)	RE 500 mg + Metformin (N = 16)	RE 750 mg + Metformin (N = 17)
All Adverse Event (AE) N(%)
Any AE	3 (18%)	6 (38%)	4 (24%)
Diarrhoea	1 (6%)	3^a (19%)	1 (6%)
Nausea	1^a (6%)	1 (6%)	1 (6%)
Thirst	1 (6%)	0	1^a (6%)
Vomiting	0	1^a (6%)	1 (6%)
Dizziness	0	1 (6%)	1 (6%)
Supraventricular tachycardia	0	1^a (6%)	0
Urinary tract infection	1^b (6%)		0
Dyslipidemia	0	1^b (6%)	0

AE Adverse event, RE Remogliflozinetabonate ^a determined to be drug related adverse event, one of 3 events of diarrhoea with RE 500 mg + Met determined to be drug related, ^b post therapy adverse events occurred after last dose

ISSN: 2050-6511